Skip to main content
. Author manuscript; available in PMC: 2014 Aug 7.
Published in final edited form as: Br J Haematol. 2010 Apr 29;150(1):72–82. doi: 10.1111/j.1365-2141.2010.08211.x

Figure 1. Adverse Events.

Figure 1

A. Most common grade 1 or 2 non-haematological adverse events seen in patients on the trial. B. Most common grade 3 or 4 adverse events seen in patients on the trial. The bar graphs express a percentage. The numbers next to each bar represent actual numbers of events. LVEF, left ventricular ejection fraction; GI, gastrointestinal; TLS, tumour lysis syndrome.